{
  "context": {
    "rules": [
      "Rule1: Under the condition that the drug treatment is effective, the pharmaceutical company is profitable.",
      "Rule2: Whenever the statistical analysis is robust, then if the clinical results are positive, the drug treatment is effective.",
      "Rule3: Either the statistical analysis is robust or the patient data is reliable.",
      "Rule4: Either the sample selection is biased, or if the patient data is reliable, then positive clinical results lead to effective drug treatment.",
      "Rule5: In the event that the phase 3 trial is completed, then if safety issues are identified, the side effects are dangerous.",
      "Rule6: Whenever the FDA review is accelerated, then if safety issues are identified, the side effects are dangerous.",
      "Rule7: Whenever the market share increases, either the phase 3 trial was completed or the FDA review was accelerated.",
      "Rule8: If the public perception is positive, then the market share increases.",
      "Rule9: Either the media coverage is negative, or if the marketing campaign is launched, the public perception is positive.",
      "Rule10: Assuming that the data validation is thorough, then if the patient data is reliable, then positive clinical results lead to effective drug treatment.",
      "Rule11: Under the condition that the expert review is independent, then if the patient data is reliable, then positive clinical results imply effective drug treatment.",
      "Rule12: Either the research budget is adequate or the industry funding is private.",
      "Rule13: Provided that the industry funding is private, the expert review is independent.",
      "Rule14: If the research methodology is transparent, then it is not the case that the research data is fraudulent.",
      "Rule15: Whenever the journal article is published, the drug is approved.",
      "Rule16: In the event that the peer review is credible, it is not the case that the statistical results were manipulated.",
      "Rule17: If the journal article is rejected, then it is not the case that the clinical trial was discontinued.",
      "Rule18: Assuming that the funding source conflicts with the ethics committee, it does not hold that the funding source is compliant with regulations.",
      "Rule19: Either the funding source conflicts with the ethics committee, or either the journal article is published or the journal article is rejected.",
      "Rule20: Either the patient screening is proper or the informed consent is not valid.",
      "Rule21: If the pilot study is successful, then the pharmaceutical company is profitable.",
      "Rule22: Either the pilot study is successful or the clinical results are positive.",
      "Rule23: If it is not the case that if the research budget is adequate then the data validation is thorough, then the research data is fraudulent.",
      "Rule24: If it does not hold that if the funding source conflicts with the ethics committee then the funding source is compliant with regulations, then the informed consent is valid.",
      "Rule25: If it is not the case that if the research methodology is not transparent then the raw data is accessible, then the statistical results were manipulated.",
      "Rule26: In the event that the pharmaceutical company is not profitable, the clinical trial was discontinued.",
      "Rule27: Under the condition that the pharmaceutical company is not profitable, safety issues were identified.",
      "Rule28: Whenever the pharmaceutical company is not profitable, it does not hold that the side effects are dangerous."
    ],
    "facts": [
      "Fact1: The marketing campaign was launched.",
      "Fact2: The peer review is credible.",
      "Fact3: The sample selection is not biased.",
      "Fact4: The drug is not approved.",
      "Fact5: The media coverage is not negative.",
      "Fact6: The raw data is not accessible.",
      "Fact7: The patient screening is not proper."
    ]
  },
  "question": "The pharmaceutical company is profitable."
}